UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2020
Commission File Number: 001-39137
AnPac Bio-Medical Science Co., Ltd.
(Registrants name)
801 Bixing Street, Bihu County
Lishui, Zhejiang Province 323006
The Peoples Republic of China
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (7): o
EXHIBIT INDEX
Exhibit Number |
|
Description |
Exhibit 99.1 |
|
AnPac Bio Announces Appointment of New Chief Financial Officer |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
AnPac Bio-Medical Science Co., Ltd. | |
|
(Registrant) | |
|
|
|
Date: June 3, 2020 |
By: |
/s/ Dr. Chris Chang Yu |
|
Name: |
Dr. Chris Chang Yu |
|
Title: |
Chairman of the Board of Directors and Chief Executive Officer |